Merck to Acquire Verona Pharma for Approximately $10 Billion
July 9, 2025
Merck, through a subsidiary, entered into a definitive agreement to acquire Verona Pharma in a transaction valued at approximately $10 billion (at $107 per ADS). The acquisition is intended to add Ohtuvayre (ensifentrine) to Merck’s cardio-pulmonary pipeline, following FDA approval for COPD in June 2024.
- Buyers
- Merck
- Targets
- Verona Pharma plc
- Industry
- Pharmaceuticals
- Location
- United Kingdom
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.